Clinical Trial

Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multicenter, open-label, multi-cohort phase Ib/II clinical study to evaluate the efficacy and safety of TQB2930 in combination with TQB2102 in patients with HER2-expressing advanced solid tumors.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-06-09
notable Trial sites expanded: 0 -> 3 locations 2026-06-09
Trial Details
NCT Number NCT07512583
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions Advanced Solid Tumor
Enrollment 178 participants
Start Date 2026-05-27
Primary Completion 2028-03 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-08